[Intravitreal bevacizumab for chronic central serous chorioretinopathy]. / Intravitreales Bevacizumab bei chronischer Retinopathia centralis serosa.
Ophthalmologe
; 105(10): 943-5, 2008 Oct.
Article
em De
| MEDLINE
| ID: mdl-18214491
ABSTRACT
Central serous chorioretinopathy (CSCR) can lead to permanent visual loss in chronic cases. We report on a 57-year-old female patient with persistent findings over 6 months despite conservative therapy. A single intravitreal injection of bevacizumab led to a rapid morphologic and functional restitution without relapse or complication during the 19 weeks period after injection. Intravitreal injection of bevacizumab could be a therapeutic option for the treatment of chronic CSCR, however the results of appropriate studies must be awaited before it can be introduced into routine use.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Coriorretinite
/
Anticorpos Monoclonais
Idioma:
De
Ano de publicação:
2008
Tipo de documento:
Article